ABIONYX Pharma SA (ABNX) Stock Statistics & Valuation Metrics

ABIONYX Pharma SA has a market cap or net worth of €117.11M. The enterprise value is €42.98M.

ABIONYX Pharma SA has 34,931,010 shares outstanding. The number of shares has decreased by -2.65% in one year.

ABIONYX Pharma SA’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -41.03%.

The current PE Ratio of ABIONYX Pharma SA is ―. ABIONYX Pharma SA’s PEG ratio is -1.09.

In the last 12 months, ABIONYX Pharma SA had revenue of 4.60M and earned -4.40M in profits. Earnings per share was -0.13.

In the last 12 months, operating cash flow was -3.43M and capital expenditures -139.00K, giving a free cash flow of -3.40M billion.

ABIONYX Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

ABIONYX Pharma SA upcoming earnings date is Mar 17, 2026, During Market Hours (Confirmed).

ABIONYX Pharma SA as a current ratio of 1.58, with Debt / Equity ratio of 76.06%

In the past 12 months, ABIONYX Pharma SA has paid -1.07M in taxes.

ABIONYX Pharma SA EV to EBITDA ratio is -8.04, with an EV/FCF ratio of -11.01.

ABIONYX Pharma SA has €3.38M in cash and marketable securities with €4.12M in debt, giving a net cash position of -€743.00K billion.

Gross margin is 18.90%, with operating margin of -121.13%, and net profit margin of -95.65%.

The average price target for ABIONYX Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is Hold